SCHEMBL4609340

SCHEMBL4609340

CCCc1ccc(C(=O)Nc2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
ATM Q13315 1/20 0.63
ABCG2 Q9UNQ0 1/20 0.60
PTPN1 P18031 1/20 0.60
TRPV1 Q8NER1 2/20 0.58
PSMD14 O00487 1/20 0.58
CACNA1B Q00975 1/20 0.58
APBA1 Q02410 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
MAPK1 P28482 1/20 0.57
ENPP1 P22413 1/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
PLK1 P53350 1/20 0.57
KDM4E B2RXH2 1/20 0.56
PKM P14618 1/20 0.55
NAMPT P43490 1/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610276 1.00 NPC1 (0.63) NPC1RAB9AATMABCG2PTPN1
SCHEMBL4610444 0.91 TRPV1 (0.72) NPC1RAB9AATMPTPN1TRPV1
SCHEMBL4611858 0.91 TRPV1 (0.72) NPC1RAB9AATMPTPN1TRPV1
SCHEMBL4122892 0.89 MAPT (0.64) NPC1RAB9AABCG2SMN1; SMN2MAPK1
SCHEMBL4611024 0.89 NPC1 (0.69) NPC1RAB9AATMPTPN1PSMD14
SCHEMBL4608963 0.89 NPC1 (0.69) NPC1RAB9AATMPTPN1PSMD14
SCHEMBL2836041 0.89 TRPV1 (0.64) NPC1RAB9AATMTRPV1PLK1
SCHEMBL8867191 0.88 NPC1 (0.63) NPC1RAB9AATMPTPN1PSMD14
SCHEMBL8867185 0.88 NPC1 (0.63) NPC1RAB9AATMPTPN1PSMD14
SCHEMBL1807631 0.87 CYP4A11 (0.68) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP disclosed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US disclosed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 NPC1 2347/4885RAB9A 4487/4885ATM 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.